Pharmacodynamics of oestrogens and progestogens

Cephalalgia

Volumn 20, Issue 3, 2000, Pages 200-207

  De Lignieres B ^a   Silberstein, S ^a,b  

^a HÂpital Necher   (France)

^b JEFFERSON HEADACHE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; DESOGESTREL; ESTRADIOL; ESTROGEN DERIVATIVE; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; NANDROLONE; NORETHISTERONE; NORGESTIMATE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; SEX HORMONE; TESTOSTERONE;

ARTICLE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG IMPLANT; DRUG USE; ESTROGEN RELEASE; PHARMACODYNAMICS; POSTMENOPAUSE; PROGESTERONE RELEASE;

CONTRACEPTIVES, ORAL; ESTRADIOL; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; PROGESTERONE; PROGESTINS;

EID: 0034454465     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2000.00042.x     Document Type: Article

References (70)

1. Estrogen receptor β - A novel receptor opens up new possibilities for cancer diagnosis and treatment
2. Molecular mechanisms of steroid hormone action
3. Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities
4. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
5. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
6. Hormone replacement therapy and heart disease prevention
7. Hormone replacement therapy and endometrial cancer: Are current regimens safe?
8. Estradiol and progesterone regulate the proliferation of human breast epithelial cells
9. Progestogens and cardiovascular disease. A critical review
10. Cellular characterization of adipose tissue from body sites of women
11. Estrogen synthesis, estrogen metabolism and functional estrogen receptors in rat arterial smooth muscle cells in culture
12. Local estradiol metabolism in osteoblast- and osteoclast-like cells
13. Pulsatile secretion of LH, FSH, Prolactin, oestradiol and progesterone during the human menstrual cycle
14. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women
15. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle
16. Cyclical variation in paroxysmal supraventricular tachycardia in women
17. Cardiovascular protection by estrogen - A calcium antagonist effect?
18. Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women
19. The case for a non plasma lipoprotein etiology of reduced vascular risk in estrogen replacement therapy
20. Women have a larger and less athrogenic low density lipoprotein particle size than men
21. Normal triglyceride levels and coronary artery disease events: The Baltimore coronary observational long-term study
22. Triglycerides and coronary risk in women and the elderly
23. Transdermal estrogen replacement therapy: Beneficial effects on hemostatic risk factors for cardiovascular disease
24. Lipoprotein subfraction changes in normal pregnancy: Threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein
25. Changes in activated protein C resistance during normal pregnancy
26. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: Comparison with men
27. Age at menopause as a risk factor for cardiovascular mortality
28. The vascular protective effects of estrogen
29. Progesterone is neuroprotective after transient middle cerebral artery occlusion in male rats
30. Influence of route of administration on progesterone metabolism
31. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro
32. Progesterone inhibits arterial smooth muscle cell proliferation
33. Desogestrel, norgestimate, and gestodene: The newer progestins
34. Investigations of pharmacokinetics of ethinylestradiol to specific consideration of a possible first-pass effect in women
35. Oral contraceptives and metabolic risk markers for coronary heart disease
36. Effects of three types of combined OC pills on blood coagulation, fibrinolysis and platelet fuction
37. Plasma lipids and desogestrel and ethinyl estradiol: A meta-analysis
38. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
39. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation
40. Use of low-dose oral contraceptives and stroke in young women
41. Third generation oral contraceptive and heritable thrombophilia as risk factors of non-fatal venous thromboembolism
42. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagens components
43. Oral contraception and risk of a cerebral thromboembolic attack: Results of a case-control study
44. Oral contraceptives and myocardial infarction
45. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus
46. Bone mineral density in women using depot medroxyprogesterone acetate for contraception
47. Progesterone implants enhance SIV vaginal transmission and early virus load
48. Chlamydia trachomatis infection in the female reproductive tract of the rat: Influence of progesterone on infectivity and immune response
49. Pharmacology of conjugated oestrogens
50. Cardiovascular effects of estrogen and lipid-lowering therapies in post-menopausal women
51. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women
52. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
53. Can postmopausal hormone replacement improve plasma lipids in women with diabetes?
54. Coagulation activation following estrogen administration to postmenopausal women
55. A clinical trial of premarin in cerebrovascular disease
56. Cardiovascular risk and use of estrogens or estrogen-progestagen combinations
57. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
58. Risk of venous thromboembolism in users of hormone replacement therapy
59. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
60. Risk of venous thrombosis with hormone replacement therapy
61. Prospective study of exogenous hormones and risk of pulmonary embolism in women
62. Hormone replacement therapy and risk of non-fatal stroke
63. Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17β-estradiol
64. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women
65. Lack of effect of raloxifene on coronary atherosclerosis of postmenopausal monkeys - Authors resonse
66. Pharmacokinetics of percutaneous estradiol: A crossover study using a gel and a transdermal system in comparison with oral micronized estradiol
67. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm
68. Progestin enhances vasoconstrictor responses in postmenopausal women receiving estrogen replacement therapy
69. Effects of estrogen and progestin on aortic size and compliance in postmenopausal women
70. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women